T. Rowe Price Associates
FLNA

T. Rowe Price Associates’s Filana Therapeutics FLNA Stock Holding History

T. Rowe Price Associates’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49K Buy
40,860
+9,492
+30% +$13.5K ﹤0.01% 3194
2026
Q1 		$54K Hold
31,368
– – ﹤0.01% 3067
2025
Q4 		$63K Buy
+31,368
New +$100K ﹤0.01% 3011
2025
Q3 		– Sell
-35,868
Closed -$65K – 3113
2025
Q2 		$65K Buy
35,868
+4,441
+14% +$7.9K ﹤0.01% 2967
2025
Q1 		$48K Sell
31,427
-4,939
-14% -$12.5K ﹤0.01% 2937
2024
Q4 		$86K Buy
36,366
+1,032
+3% +$18.1K ﹤0.01% 2863
2024
Q3 		$1.04M Buy
35,334
+550
+2% +$12.7K ﹤0.01% 1955
2024
Q2 		$430K Buy
34,784
+3,457
+11% +$72.9K ﹤0.01% 2248
2024
Q1 		$636K Buy
31,327
+1,456
+5% +$33.5K ﹤0.01% 2115
2023
Q4 		$673K Buy
29,871
+2,282
+8% +$48.2K ﹤0.01% 2046
2023
Q3 		$460K Buy
27,589
+870
+3% +$17.2K ﹤0.01% 2146
2023
Q2 		$656K Sell
26,719
-248
-0.9% -$5.97K ﹤0.01% 2009
2023
Q1 		$651K Buy
26,967
+1,566
+6% +$43.4K ﹤0.01% 1996
2022
Q4 		$750K Sell
25,401
-2,380
-9% -$85.5K ﹤0.01% 1933
2022
Q3 		$1.16M Buy
27,781
+929
+3% +$25.1K ﹤0.01% 1684
2022
Q2 		$755K Sell
26,852
-1,393
-5% -$35.2K ﹤0.01% 2041
2022
Q1 		$1.05M Buy
28,245
+5,344
+23% +$226K ﹤0.01% 1986
2021
Q4 		$1M Buy
22,901
+1,639
+8% +$85.9K ﹤0.01% 2041
2021
Q3 		$1.32M Sell
21,262
-647
-3% -$54K ﹤0.01% 1908
2021
Q2 		$1.87M Sell
21,909
-13,797
-39% -$739K ﹤0.01% 1765
2021
Q1 		$1.6M Buy
35,706
+22,209
+165% +$873K ﹤0.01% 1817
2020
Q4 		$92K Buy
+13,497
New +$121K ﹤0.01% 2633

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

T. Rowe Price Associates's FLNA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Filana Therapeutics (FLNA) stake by 30% in Q2 2026, buying an estimated $13.5K and bringing the position to 40,860 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #3194.

T. Rowe Price Associates first reported a position in FLNA in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.87M in Q2 2021. 85 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • T. Rowe Price Associates held 40,860 shares of Filana Therapeutics worth $49K as of Q2 2026.
  • T. Rowe Price Associates bought 9,492 Filana Therapeutics shares in Q2 2026, an estimated $13.5K.
  • Filana Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3194 holding.
  • T. Rowe Price Associates first reported a position in Filana Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • T. Rowe Price Associates's Filana Therapeutics position peaked at $1.87M in Q2 2021.
  • 85 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.